1. |
Overman RA, Gourlay ML, Deal CL, et al. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporosis International, 2015.[Epub ahead of print].
|
2. |
Briota K, Cortetb B, Roux C, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine, 2014, 81(6):493-501.
|
3. |
den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep, 2011, 13(3):233-240.
|
4. |
田丽花, 梁敏, 张劼, 等. 糖皮质激素性骨质疏松大鼠模型建立的研究. 广西医科大学学报, 2013, 30(1):5-7.
|
5. |
Pasqualetti S, Congiu T, Banfi G, et al. Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale. Int J Exp Pathol, 2015.[Epub ahead of print].
|
6. |
Hulley PA, Conradie MM, Langeveldt CR, et al. Glucocorticoid-induced osteoporosis in the rat is prevented by tyrosine phosphatase inhibitor, sodium orthovanadate. Bone, 2002, 31(1):220-229.
|
7. |
Wimalawansa SJ, Simmons DJ. Prevention of corticosteroid induced bone loss with alendronate. Proc Soc Exp Biol Med, 1998, 217(2):162-167.
|
8. |
Kim HK, Kim MG, Leem KH. Osteogenic activity of collagen peptide via ERK/MAPK pathway mediated boosting of collagen synthesis and its therapeutic efficacy in osteoporotic bone by back-scattered electron imaging and microarchitecture analysis. Molecules, 2013, 18(12):15474-15489.
|
9. |
Ma B, Zhang Q, Wu D, et al. Strontium fructose 1, 6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin, 2012, 33(4):479-89.
|
10. |
周乐, 吴铁, 崔燎. 淫羊藿调节BMP-7预防糖皮质激素致大鼠骨损害的研究. 中国骨质疏松杂志, 2014, 20(3):234-237, 241.
|
11. |
陈婷颖, 任伟. 成人生长激素缺乏症与骨质疏松. 现代医药卫生, 2014, 30(13):1965-1967.
|
12. |
Lin S, Huang J, Zheng L, et al. Glucocorticoid-induced osteoporosis in growing rats. Calcif Tissue Int, 2014, 95(4):362-373.
|
13. |
戴哲浩, 康意军, 吕国华, 等. 糖皮质激素对成年大鼠骨量的影响. 中国骨质疏松杂志, 2014, 20(4):366-371.
|
14. |
柯务. 体重指数与男性骨质疏松关系的研究. 中国现代医生, 2013, 51(21):25-26.
|
15. |
Hamidi MS, Corey PN, Cheung AM. Effects of vitamin E on bone turnover markers among US postmenopausal women. J Bone Miner Res, 2012, 27(6):1368-1380.
|
16. |
Sbrocchi AM, Rauch F, Matzinger M, et al. Vertibral fractures despite normal spine bone mineral density in a boy with nephritic syndrome. Pediatr Nephrol, 2011, 26(1):139-142.
|
17. |
Li M, Li Y, Deng W, et al. Chinese bone turnover marker study:reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal Peptide by age and gender. PLoS One, 2014, 9(8):e103841.
|
18. |
欧萌萌, 黄建荣. 绝经后妇女骨质疏松症患者血清β-Crosslaps、PINP和N-MID检测的评价. 标记免疫分析与临床, 2011, 18(4):238-240.
|
19. |
Farahmand P, Marin F, Hawkins F, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int, 2013, 24(12):2971-2981.
|
20. |
刘晓红, 卢文, 钱浩, 等. 糖皮质激素对肾小球疾病患者骨密度和骨转换指标的影响. 实用医学杂志, 2014, 30(22):3583-3586.
|
21. |
McManus MM, Grill RJ. Longitudinal evaluation of mouse hind limb bone loss after spinal cord injury using novel, in vivo, methodology. J Vis Exp, 2011, (58):e3246.
|